Influenza

Critical Care Medicine

Volumn 36, Issue 9, 2008, Pages 2660-2666

  Beigel, John H ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

Avian flu; Complications; Influenza; Pandemic; Pneumonia; Treatment

Indexed keywords

ACETYLSALICYLIC ACID; AMANTADINE; DAPTOMYCIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LINEZOLID; OSELTAMIVIR; PERAMIVIR; PLACEBO; RIMANTADINE; ROTADISK; T 705; UNCLASSIFIED DRUG; VANCOMYCIN; ZANAMIVIR; ANTIVIRUS AGENT;

ACUTE CORONARY SYNDROME; AVIAN INFLUENZA; BACTERIAL PNEUMONIA; BRONCHITIS; BRONCHOSPASM; CANCER PATIENT; CAUSE OF DEATH; CHILL; CHRONIC BRONCHITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMMUNITY ACQUIRED PNEUMONIA; COUGHING; DIAGNOSTIC KIT; DIARRHEA; DISEASE EXACERBATION; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DEGRADATION; DRUG HALF LIFE; DRUG MEGADOSE; DRUG PENETRATION; ENCEPHALITIS; FEVER; GRAFT RECIPIENT; HEADACHE; HOSPITALIZATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPOXEMIA; IMMUNOASSAY; IMMUNOCOMPROMISED PATIENT; IMMUNOFLUORESCENCE; IMMUNOFLUORESCENCE MICROSCOPY; INCIDENCE; INCUBATION TIME; INFECTION CONTROL; INFLUENZA; INFLUENZA VIRUS A; INFLUENZA VIRUS A H10N7; INFLUENZA VIRUS A H5N1; INFLUENZA VIRUS A H7N3; INFLUENZA VIRUS A H7N7; INFLUENZA VIRUS A H9N2; INFLUENZA VIRUS B; INFLUENZA VIRUS C; INTENSIVE CARE UNIT; LEUKEMIA; LEUKOPENIA; LUNG INFILTRATE; MALAISE; MEDLINE; MORBIDITY; MORTALITY; MYALGIA; NAUSEA; NUCLEIC ACID ANALYSIS; PANDEMIC; PNEUMONIA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROFESSIONAL KNOWLEDGE; RESCUE PERSONNEL; REVIEW; REYE SYNDROME; RHINORRHEA; SENSITIVITY AND SPECIFICITY; SEROLOGY; SORE THROAT; SPUTUM ANALYSIS; SWEATING; TEACHING HOSPITAL; TERTIARY HEALTH CARE; UNITED STATES; VIRUS CULTURE; VIRUS MYOCARDITIS; VIRUS REPLICATION; VIRUS SHEDDING; VIRUS TRANSMISSION; VOMITING; ANIMAL; BIRD; DISEASE TRANSMISSION; EPIDEMIC; GENETIC REASSORTMENT; GENETICS; ISOLATION AND PURIFICATION; METHODOLOGY; SEASON; VIROLOGY;

ANIMALS; ANTIVIRAL AGENTS; BIRDS; DISEASE OUTBREAKS; HUMANS; INFECTION CONTROL; INFLUENZA A VIRUS; INFLUENZA IN BIRDS; INFLUENZA, HUMAN; REASSORTANT VIRUSES; SEASONS; UNITED STATES;

EID: 53049110527     PISSN: 00903493     EISSN: 15300293     Source Type: Journal    
DOI: 10.1097/CCM.0b013e318180b039     Document Type: Review

References (87)

1. Dushoff J, Plotkin JB, Viboud C, et al: Mortality due to influenza in the United States - An annualized regression approach using multiple-cause mortality data. Am J Epidemiol 2006; 163:181-187
2. Diseases NFfi, NFID Consumer Survey: Public Perception of Influenza, Vaccination and Treatment Options. NFID, 2006
3. King WD, Woolhandler SJ, Brown AF, et al: Brief report: Influenza vaccination and health care workers in the United States. J Gen Intern Med 2006; 21:181-184
4. Rothberg MB, Bonner AB, Rajab MH, et al: Effects of local variation, specialty, and beliefs on antiviral prescribing for influenza. Clin Infect Dis 2006; 42:95-99
5. Pons MW: Isolation of influenza virus ribonucleoprotein from infected cells. Demonstration of the presence of negative-stranded RNA in viral RNP. Virology 1971; 46: 149-160
6. Tumova B, Pereira HG: Antigenic relationship between influenza A viruses of human and animal origin. Bull World Health Organ 1968; 38:415-420
7. Kimura H, Abiko C, Peng G, et al: Interspecies transmission of influenza C virus between humans and pigs. Virus Res 1997; 48: 71-79
8. Osterhaus AD, Rimmelzwaan GF, Martina BE, et al: Influenza B virus in seals. Science 2000; 288:1051-1053
9. Matsuzaki Y, Katsushima N, Nagai Y, et al: Clinical features of influenza C virus infection in children. J Infect Dis 2006; 193: 1229-1235
10. Homma M, Ohyama S, Katagiri S: Age distribution of the antibody to type C influenza virus. Microbiol Immunol 1982; 26:639-642
11. Springer GF, Schwick HG, Fletcher MA: The relationship of the influenza virus inhibitory activity of glycoproteins to their molecular size and sialic acid content. Proc Natl Acad Sci USA 1969; 64:634-641
12. Suzuki Y, Ito T, Suzuki T, et al: Sialic acid species as a determinant of the host range of influenza A viruses. J Virol 2000; 74: 11825-11831
13. Gottschalk A: The influenza virus neuraminidase. Nature 1958; 181:377-378
14. Webster RG, Bean WJ, Gorman OT, et al: Evolution and ecology of influenza A viruses. Microbiol Rev 1992; 56:152-179
15. Beigel JH, Farrar J, Han AM, et al: Avian influenza A (H5N1) infection in humans. N Engl J Med 2005; 353:1374-1385
16. Dowdle WR, Coleman MT, Gregg MB: Natural history of influenza type A in the United States, 1957-1972. Prog Med Virol 1974; 17: 91-135
17. Suwanjutha S, Chantarojanasiri T, Watthana-kasetr S, et al: A study of nonbacterial agents of acute lower respiratory tract infection in Thai children. Rev Infect Dis 1990; 12 (Suppl 8):S923-S928
18. Nguyen HL, Saito R, Ngiem HK, et al: Epidemiology of influenza in Hanoi, Vietnam, from 2001 to 2003. J Infect 2007; 55:58-63
19. Dowell SF, Ho MS: Seasonality of infectious diseases and severe acute respiratory syn-drome-what we don't know can hurt us. Lancet Infect Dis 2004; 4:704-708
20. Adachi M, Matsukura S, Tokunaga H, et al: Expression of cytokines on human bronchial epithelial cells induced by influenza virus A. Int Arch Allergy Immunol 1997; 113: 307-311
21. Ottolini MG, Blanco JC, Eichelberger MC, et al: The cotton rat provides a useful smallanimal model for the study of influenza virus pathogenesis. J Gen Virol 2005; 86(Pt 10): 2823-2830
22. Papineni RS, Rosenthal FS: The size distribution of droplets in the exhaled breath of healthy human subjects. J Aerosol Med 1997; 10:105-116
23. Bridges CB, Kuehnert MJ, Hall CB: Transmission of influenza: Implications for control in health care settings. Clin Infect Dis 2003; 37:1094-1101
24. Brankston G, Gitterman L, Hirji Z, et al: Transmission of influenza A in human beings. Lancet Infect Dis 2007; 7:257-265
25. Boone SA, Gerba CP: The occurrence of influenza A virus on household and day care center fomites. J Infect 2005; 51:103-109
26. Tablan OC, Anderson LJ, Besser R, et al: Guidelines for preventing health-care-associated pneumonia, 2003: Recommendations of CDC and the Healthcare Infection Control Practices Advisory Committee. MMWR Recomm Rep 2004; 53:1-36
27. Fowler RA, Guest CB, Lapinsky SE, et al: Transmission of severe acute respiratory syndrome during intubation and mechanical ventilation. Am J Respir Crit Care Med 2004; 169:1198-1202
28. Lauderdale TL, Chang FY, Ben RJ, et al: Etiology of community acquired pneumonia among adult patients requiring hospitalization in Taiwan. Respir Med 2005; 99: 1079-1086
29. Blanquer J, Blanquer R, Borras R, et al: Aetiology of community acquired pneumonia in Valencia, Spain: A multicentre prospective study. Thorax 1991; 46:508-511
30. Nauffal D, Menendez R, Morales P, et al: [Community viral pneumonia in the adult population: a prospective multicenter study of 62 cases. The Pneumonia Study Group of the Community of Valencia]. Rev Clin Esp 1990; 187:229-232
31. Numazaki K, Chiba S, Umetsu M, et al: Etiological agents of lower respiratory tract infections in Japanese children. In Vivo 2004; 18:67-71
32. Bowden RA: Respiratory virus infections after marrow transplant: the Fred Hutchinson Cancer Research Center experience. Am J Med 1997; 102:27-30; discussion 42-23
33. de Roux A, Marcos MA, Garcia E, et al: Viral community-acquired pneumonia in nonimmunocompromised adults. Chest 2004; 125: 1343-1351
34. Barker WH, Mullooly JP: Pneumonia and influenza deaths during epidemics: implications for prevention. Arch Intern Med 1982; 142:85-89
35. Ison MG, Gnann JW Jr, Nagy-Agren S, et al: Safety and efficacy of nebulized zanamivir in hospitalized patients with serious influenza. Antivir Ther 2003; 8:183-190
36. Weinstock DM, Gubareva LV, Zuccotti G: Prolonged shedding of multidrug-resistant influenza A virus in an immunocompromised patient. N Engl J Med 2003; 348: 867-868
37. Treanor JJ, Hayden FG, Vrooman PS, et al: Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: A randomized controlled trial. US Oral Neuraminidase Study Group. JAMA 2000; 283:1016-1024
38. Couch RB, Douglas RG Jr, Fedson DS, et al: Correlated studies of a recombinant influenza-virus vaccine. 3. Protection against experimental influenza in man. J Infect Dis 1971; 124:473-480
39. Whitley RJ, Hayden FG, Reisinger KS, et al: Oral oseltamivir treatment of influenza in children. Pediatr Infect Dis J 2001; 20: 127-133
40. Smit M, Beynon KA, Murdoch DR, et al: Comparison of the NOW Influenza A & B, NOW Flu A, NOW Flu B, and Directigen Flu A + B assays, and immunofluorescence with viral culture for the detection of influenza A and B viruses. Diagn Microbiol Infect Dis 2007; 57:67-70
41. Weinberg A: Evaluation of three influenza A and B rapid antigen detection kits-update. Clin Diagn Lab Immunol 2005; 12:1010
42. Hurt AC, Alexander R, Hibbert J, et al: Performance of six influenza rapid tests in detecting human influenza in clinical specimens. J Clin Virol 2007; 39:132-135
43. Steininger C, Kundi M, Aberle SW, et al: Effectiveness of reverse transcription-PCR, virus isolation, and enzyme-linked immunosorbent assay for diagnosis of influenza A virus infection in different age groups. J Clin Microbiol 2002; 40:2051-2056
44. Petric M, Comanor L, Petti CA: Role of the laboratory in diagnosis of influenza during seasonal epidemics and potential pandemics. J Infect Dis 2006; 194 (Suppl 2):S98-S110
45. Zitterkopf NL, Leekha S, Espy MJ, et al: Relevance of influenza a virus detection by PCR, shell vial assay, and tube cell culture to rapid reporting procedures. J Clin Microbiol 2006; 44:3366-3367
46. Templeton KE, Scheltinga SA, Beersma MF, et al: Rapid and sensitive method using multiplex real-time PCR for diagnosis of infections by influenza a and influenza B viruses, respiratory syncytial virus, and parainfluenza viruses 1, 2, 3, and 4. J Clin Microbiol 2004; 42:1564-1569
47. Syrmis MW, Whiley DM, Thomas M, et al: A sensitive, specific, and cost-effective multiplex reverse transcriptase-PCR assay for the detection of seven common respiratory viruses in respiratory samples. J Mol Diagn 2004; 6:125-131
48. Sampath R, Hall TA, Massire C, et al: Rapid identification of emerging infectious agents using PCR and electrospray ionization mass spectrometry. Ann N Y Acad Sci 2007; 1102: 109-120
49. Schanzer DL, Tam TW, Langley JM, et al: Influenza-attributable deaths, Canada 1990-1999. Epidemiol Infect 2007; 135: 1109-1116
50. Centers for Disease Control and Prevention (CDC): Severe methicillin-resistant Staphylococcus aureus community-acquired pneumonia associated with influenza-Louisiana and Georgia, December 2006-January 2007. MMWR Morb Mortal Wkly Rep 2007; 56: 325-329
51. Adam H, McGeer A, Simor A: Fatal case of post-influenza, community-associated MRSA pneumonia in an Ontario teenager with subsequent familial transmission. Can Commun Dis Rep 2007; 33:45-48
52. Micek ST, Dunne M, Kollef MH: Pleuropulmonary complications of Panton-Valentine leukocidin-positive community-acquired methicillin-resistant Staphylococcus aureus: Importance of treatment with antimicrobials inhibiting exotoxin production. Chest 2005; 128:2732-2738
53. Karjalainen J, Nieminen MS, Heikkila J: Influenza A1 myocarditis in conscripts. Acta Med Scand 1980; 207:27-30
54. Onitsuka H, Imamura T, Miyamoto N, et al: Clinical manifestations of influenza a myocarditis during the influenza epidemic of winter 1998-1999. J Cardiol 2001; 37:315-323
55. Greaves K, Oxford JS, Price CP, et al: The prevalence of myocarditis and skeletal muscle injury during acute viral infection in adults: measurement of cardiac troponins I and T in 152 patients with acute influenza infection. Arch Intern Med 2003; 163: 165-168
56. Bowles NE, Ni J, Kearney DL, et al: Detection of viruses in myocardial tissues by polymerase chain reaction. Evidence of adenovirus as a common cause of myocarditis in children and adults. J Am Coll Cardiol 2003; 42:466-472
57. McGovern PC, Chambers S, Blumberg EA, et al: Successful explantation of a ventricular assist device following fulminant influenza type A-associated myocarditis. J Heart Lung Transplant 2002; 21:290-293
58. Nolte KB, Alakija P, Oty G, et al: Influenza A virus infection complicated by fatal myocarditis. Am J Forensic Med Pathol 2000; 21: 375-379
59. Frost FJ, Petersen H, Tollestrup K, et al: Influenza and COPD mortality protection as pleiotropic, dose-dependent effects of statins. Chest 2007; 131:1006-1012
60. Mehdi S, Franco J: Reye's syndrome in an adult: A case report. WMJ 2000; 99:23-24
61. Morishima T, Togashi T, Yokota S, et al: Encephalitis and encephalopathy associated with an influenza epidemic in Japan. Clin Infect Dis 2002; 35:512-517
62. Fujimoto S, Kobayashi M, Uemura O, et al: PCR on cerebrospinal fluid to show influenzaassociated acute encephalopathy or encephalitis. Lancet 1998; 352:873-875
63. Gurfinkel EP, de la Fuente RL, Mendiz O, et al: Influenza vaccine pilot study in acute coronary syndromes and planned percutaneous coronary interventions: The FLU Vaccination Acute Coronary Syndromes (FLUVACS) Study. Circulation 2002; 105:2143-2147
64. Visseren FL, Verkerk MS, Bouter KP, et al: Interleukin-6 production by endothelial cells after infection with influenza virus and cytomegalovirus. J Lab Clin Med 1999; 134: 623-630
65. Visseren FL, Bouwman JJ, Bouter KP, et al: Procoagulant activity of endothelial cells after infection with respiratory viruses. Thromb Haemost 2000; 84:319-324
66. Wongsurakiat P, Maranetra KN, Wasi C, et al: Acute respiratory illness in patients with COPD and the effectiveness of influenza vaccination: a randomized controlled study. Chest 2004; 125:2011-2020
67. Bright RA, Shay DK, Shu B, et al: Adamantane resistance among influenza A viruses isolated early during the 2005-2006 influenza season in the United States. JAMA 2006; 295:891-894
68. Hayden FG, Jennings L, Robson R, et al: Oral oseltamivir in human experimental influenza B infection. Antivir Ther 2000; 5:205-213
69. Hayden FG, Treanor JJ, Fritz RS, et al: Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: Randomized controlled trials for prevention and treatment. JAMA 1999; 282:1240-1246
70. Nicholson KG, Aoki FY, Osterhaus AD, et al: Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Neuraminidase Inhibitor Flu Treatment Investigator Group. Lancet 2000; 355:1845-1850
71. Randomised trial of efficacy and safety of inhaled zanamivir in treatment of influenza A and B virus infections. The MIST (Management of Influenza in the Southern Hemisphere Trialists) Study Group. Lancet 1998; 352:1877-1881
72. Calfee DP, Peng AW, Cass LM, et al: Safety and efficacy of intravenous zanamivir in preventing experimental human influenza A virus infection. Antimicrob Agents Chemother 1999; 43:1616-1620
73. Hayden FG, Osterhaus AD, Treanor JJ, et al: Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenzavirus infections. GG167 Influenza Study Group. N Engl J Med 1997; 337:874-880
74. Hayden FG, Treanor JJ, Betts RF, et al: Safety and efficacy of the neuraminidase inhibitor GG167 in experimental human influenza. JAMA 1996; 275:295-299
75. Nicholson KG, Kent J, Hammersley V, et al: Acute viral infections of upper respiratory tract in elderly people living in the community: comparative, prospective, population based study of disease burden. BMJ 1997; 315:1060-1064
76. Aoki FY, Macleod MD, Paggiaro P, et al: Early administration of oral oseltamivir increases the benefits of influenza treatment. J Antimicrob Chemother 2003; 51:123-129
77. Monto AS, Gravenstein S, Elliott M, et al: Clinical signs and symptoms predicting influenza infection. Arch Intern Med 2000; 160:3243-3247
78. Kaiser L, Wat C, Mills T, et al: Impact of oseltamivir treatment on influenza-related lower respiratory tract complications and hospitalizations. Arch Intern Med 2003; 163: 1667-1672
79. Mcgeer A, Green KA, Plevneshi A, et al. Antiviral therapy and outcomes of influenza requiring hospitalization in Ontario, Canada. Clin Infect Dis 2007; 45:1568-1575
80. Schunemann HJ, Hill SR, Kakad M, et al: WHO Rapid Advice Guidelines for pharmacological management of sporadic human infection with avian influenza A (H5N1) virus. Lancet Infect Dis 2007; 7:21-31
81. Khoo SH, Hajia M, Storey CC, et al: Influenza-like episodes in HIV-positive patients: the role of viral and 'atypical' infections. Aids 1998; 12:751-757
82. Radwan HM, Cheeseman SH, Lai KK, et al: Influenza in human immunodeficiency virus-infected patients during the 1997-1998 influenza season. Clin Infect Dis 2000; 31: 604-606
83. Safrin S, Rush JD, Mills J: Influenza in patients with human immunodeficiency virus infection. Chest 1990; 98:33-37
84. Lin JC, Nichol KL: Excess mortality due to pneumonia or influenza during influenza seasons among persons with acquired immunodeficiency syndrome. Arch Intern Med 2001; 161:441-446
85. Ison MG, Hayden FG: Viral infections in immunocompromised patients: What's new with respiratory viruses?. Curr Opin Infect Dis 2002; 15:355-367
86. Nichols WG, Guthrie KA, Corey L, et al: Influenza infections after hematopoietic stem cell transplantation: risk factors, mortality, and the effect of antiviral therapy. Clin Infect Dis 2004; 39:1300-1306
87. Ison MG, Gubareva LV, Atmar RL, et al: Recovery of drug-resistant influenza virus from immunocompromised patients: A case series. J Infect Dis 2006; 193:760-764